Halma plc ('Halma' or the
'Group')
Acquisition
Halma, the global group of
life-saving technology companies, today announces that it has
acquired Rovers Medical Devices B.V. ("Rovers").
Headquartered in Oss in the
Netherlands, Rovers designs and manufactures sample collection
devices used in the prevention and diagnostics of cervical cancer.
Rovers' products are principally for professional use and include
its Cervex-Brush®, widely recognised as the gold standard for
cervical cancer screening. Rovers' products are used in more than
90 countries, and are sold primarily to medical diagnostic
companies, as well as medical distributors, laboratories, research
institutes and governments.
The initial consideration for Rovers
is €85m (approximately £73m), on a cash- and debt-free basis, which
will be paid in cash and funded from Halma's existing facilities.
An additional consideration of up to €6m (approximately £5m) is
payable in cash, based on Rovers' performance in the period to 31
March 2025.
Rovers' unaudited revenue for the 12
months to 31 December 2023 was €12.0m (approximately £10.3m), with
Return on Sales more than double Halma's target range of 18-22%.
Rovers will be a standalone company within Halma's Healthcare
sector, led by its current management team.
Marc Ronchetti, Group Chief
Executive of Halma, said:
"Rovers will broaden the range of
markets we serve in women's health and further strengthen our
Healthcare sector's position in cancer diagnosis products. We are
excited by the opportunities we see to increase Rovers' positive
impact on public health. We expect its future growth to be driven
by increasing global cervical screening rates, supporting the World
Health Organization's strategy to accelerate the early detection of
cervical cancer."
Roel Leenders, Chief Executive
Officer of Rovers, said:
"We want to contribute to the
prevention of cancer on a global scale. This mission strongly
aligns to Halma's when it comes to improving quality of care for
patients. Many physicians work with us to develop the highest
quality screening products that are most effective for their
patients. By joining the Halma group, Rovers can grow to the next
level, adding talent development and commercial opportunities while
collaborating with a global group of like-minded businesses, that
will help us to enable better screening and diagnostics for
patients worldwide."
For further information, please
contact:
Halma plc
Marc Ronchetti, Group Chief
Executive
+44 (0)1494 721111
Steve Gunning, Group Chief Financial
Officer
Charles King, Head of Investor
Relations
+44 (0) 7776
685948
Clayton Hirst, Director of Corporate
Affairs
+44 (0) 7384 796 013
MHP
Oliver Hughes / Rachel Farrington /
Ollie Hoare
+44 (0)20 3128
8100
A copy of this announcement,
together with other information about Halma, is available at
www.halma.com.
About Halma
Halma is a global group of
life-saving technology companies, focused on growing a safer,
cleaner, healthier future for everyone, every day. Its purpose
defines the three broad markets it operates in:
· Health - Meeting the increasing demand for better healthcare as
chronic illness rises, driven by growing and ageing populations and
lifestyle changes.
· Environment - Addressing the impacts of climate change,
pollution and waste, protecting life-critical resources and
supporting scientific research.
· Safety - Protecting people's safety and the environment as
populations grow and enhancing worker safety.
It employs over 8,000 people in more
than 20 countries, with major operations in the UK, Mainland
Europe, the USA and Asia Pacific. Halma is listed on
the London Stock Exchange (LON: HLMA) and is a constituent of the
FTSE 100 index.
Halma has been named as one
of Britain's Most Admired Companies for the past five
years.
For more
information www.halma.com
ENDS
